HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Clinical trial NCT03786107 · TERMINATED

Trial details

NCT number: NCT03786107
Sponsor: Puma Biotechnology, Inc.
Status: TERMINATED
Study type: OBSERVATIONAL

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Metastatic Cervical Cancer

Start date: 2019-03-14
Primary completion: 2021-01-21
Enrollment: 1583

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.